IRVINE, CA and LIEGE, BELGIUM--(Marketwired - Jun 18, 2013) - MDxHealth SA (
The company also announced that the three-year director mandates of each of Dr. Karin Dorrepaal and Mr. Raphaël Wisniewski, as permanent representative of Edmond de Rothschild Investment Partners, have ended as of May 31, 2013. The board now consists of six members, whose mandates were approved by the company's shareholders in connection with the Annual General Meeting of Shareholders held on May 31, 2013. For additional information please refer to the company's web site at www.mdxhealth.com.
Dr. Pauwels is a serial entrepreneur who co-founded several European biotech companies, including Tibotec Virco, Galapagos Genomics, Biocartis and MDxHealth. Dr. Pauwels currently serves as chairman and CEO of Biocartis. Starting his career at the Rega Institute for Medical Research in Leuven, Dr. Pauwels pioneered the development of novel anti-HIV treatments and diagnostic tools that enable more personalized HIV therapy.
"Rudi is a great addition to our Board. His knowledge and expertise of diagnostic technologies and product development is a significant asset. The management team looks forward to utilizing his broad and seasoned perspective to help us advance MDxHealth's growth plans," noted Dr. Jan Groen, CEO of MDxHealth.
Commenting on the changes to the MDxHealth board, Mr. Edward L. Erickson, Chairman of the Board, said, "I welcome Dr. Pauwels to the board and the directors look forward to working with him to advance our strategy and continue to build the company. On behalf of the board I also offer our thanks and deep appreciation for the many years of valuable service by Dr. Dorrepaal and Mr. Wisniewski."
MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. The company's first commercial product, ConfirmMDx™ for Prostate Cancer, has been shown to help distinguish patients who have a true-negative biopsy from those who may have undetected cancer. MDxHealth helps to address a large and growing unmet medical need for better cancer diagnosis and treatment information. The company has a proprietary platform and a strong epigenetic product pipeline focused on the development of products for prostate, brain and lung cancers. The company is based in Irvine, California with a European headquarters in Liege, Belgium. For more information visit MDxHealth's website at www.mdxhealth.com.
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.
To access the PDF file, please click here: http://hugin.info/137314/R/1709911/566811.pdf